EUVIMEDEUVIMED entdecken
Open Access

Two‐Year Outcomes With a Next‐Generation Left Atrial Appendage Device: Final Results of the PINNACLE FLX Trial

Shephal K Doshi iD, Saibal Kar iD, Ashish Sadhu, Rodney Horton iD, Jose Osorio iD, Christopher Ellis iD, James Stone, Manish Shah iD, Srinivas R Dukkipati iD, Stuart Adler, Devi G Nair iD, Jamie Kim und 8 weitere

Journal of the American Heart Association · 21.02.2023 · 12 (4)

DOI: 10.1161/jaha.122.026295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 21.02.2023. Verfasst von Shephal K Doshi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Providence, Saint Johns Health Center Pacific Heart Institute Santa Monica CA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Atrial Appendage, Stroke, Embolism. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The PINNACLE FLX (Protection Against Embolism for Non‐valvular AF [Atrial Fibrillation] Patients: Investigational Device Evaluation of the Watchman FLX LAA [Left Atrial Appendage] Closure Technology) trial evaluated the safety and efficacy of a next‐generation left atrial appendage closure device (WATCHMAN FLX; Boston Scientific, Marlborough, MA). At 1 year, the study met the primary end points of safety and anatomical efficacy/appendage closure. This final report of the PINNACLE FLX trial includes the prespecified secondary end point of ischemic stroke or systemic embolism at 2 years, also making it the first report of 2‐year outcomes with this next‐generation left atrial appendage closure device. Methods and Results Patients with nonvalvular atrial fibrillation with CHA 2 DS 2 ‐VASc score ≥2 (men) or ≥3 (women), with an appropriate rationale for left atrial appendage closure, were enrolled to receive the left atrial appendage closure device at 29 US centers. Adverse events were assessed by an independent clinical events committee, and imaging was assessed by independent core laboratories. Among 395 implanted patients (36% women; mean age, 74 years; CHA 2 DS 2 ‐VASc, 4.2±1.5), the secondary efficacy end point of 2‐year ischemic stroke or systemic embolism was met, with an absolute rate of 3.4% (annualized rate, 1.7%) and an upper 1‐sided 95% confidence bound of 5.3%, which was superior to the 8.7% performance goal. Two‐year rates of adverse events were as follows: 9.3% all‐cause mortality, 5.5% cardiovascular death, 3.4% all stroke, and 10.1% major bleeding (Bleeding Academic Research Consortium 3 or 5). There were no additional systemic embolisms, device embolizations, pericardial effusions, or symptomatic device‐related thrombi after 1 year.

Conclusions

The secondary end point of 2‐year stroke or systemic embolism was met at 3.4%. In these final results of the PINNACLE FLX trial, the next‐generation WATCHMAN FLX device demonstrated favorable safety and efficacy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAtrial AppendageStrokeEmbolismIschemic StrokeMaleHumansFemaleAgedTreatment OutcomeHemorrhageCardiac Catheterization

Stichwörter der Autor:innen

WATCHMAN FLXatrial fibrillationleft atrial appendage closure

Autor:innen und Institutionen

  • Providence, Saint Johns Health Center Pacific Heart Institute Santa Monica CA.
  • Los Robles Regional Medical Center Thousand Oaks CA.
  • Phoenix Cardiovascular Research Group Phoenix AZ.
  • Texas Cardiac Arrhythmia Austin TX.
  • Arrhythmia Institute at Grandview Birmingham AL.
  • Vanderbilt University Medical Center Nashville TN.

ORCID-Profile: Shephal K Doshi, Saibal Kar, Rodney Horton, Jose Osorio, Christopher Ellis, Manish Shah, Srinivas R Dukkipati, Devi G Nair, Oussama Wazni, Matthew J Price, David R Holmes, Vivek Y Reddy

Zitieren

APA

Doshi, S. K., Kar, S., Sadhu, A., Horton, R., Osorio, J., Ellis, C., Stone, J., Shah, M., Dukkipati, S. R., Adler, S., Nair, D. G., Kim, J., Wazni, O., Price, M. J., Holmes, D. R., Shipley, R., Christen, T., Allocco, D. J., Reddy, V. Y., & PINNACLE FLX investigators [Link] (2023). Two‐Year Outcomes With a Next‐Generation Left Atrial Appendage Device: Final Results of the PINNACLE FLX Trial. Journal of the American Heart Association, 12(4). https://doi.org/10.1161/jaha.122.026295

Vancouver

Doshi SK, Kar S, Sadhu A, Horton R, Osorio J, Ellis C, et al. Two‐Year Outcomes With a Next‐Generation Left Atrial Appendage Device: Final Results of the PINNACLE FLX Trial. Journal of the American Heart Association. 2023;12(4). doi:10.1161/jaha.122.026295

BibTeX
@article{Doshi2023,
  author = {Doshi, Shephal K and Kar, Saibal and Sadhu, Ashish and Horton, Rodney and Osorio, Jose and Ellis, Christopher and Stone, James and Shah, Manish and Dukkipati, Srinivas R and Adler, Stuart and Nair, Devi G and Kim, Jamie and Wazni, Oussama and Price, Matthew J and Holmes, David R and Shipley, Robert and Christen, Thomas and Allocco, Dominic J and Reddy, Vivek Y and PINNACLE FLX investigators [Link], PINNACLE FLX investigators [Link]},
  title = {Two‐Year Outcomes With a Next‐Generation Left Atrial Appendage Device: Final Results of the PINNACLE FLX Trial},
  journal = {Journal of the American Heart Association},
  year = {2023},
  volume = {12},
  number = {4},
  doi = {10.1161/jaha.122.026295}
}
Kostenlos starten →